GoAI
Get started
PRF Technologies Ltd. logo

PRF Technologies Ltd.

PRFX

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$0.9971

−$0.0029 · -0.29%

Aug 21, 4:00 PM ET

PRFX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

19

Strong Down

Sentiment

59

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
IL
CEO
Efraim Cohen-Arazi
Listed since
Sep 1, 2020
Employees
7

Market position

Day range

Current $0.9971

52-week range

Current $0.9971

Open
$1.00
Previous close
$1.00
Volume
67.99K
0.03× average
Average volume
2.12M
Average daily volume
Market cap
80.3K USD
Beta
1.04
Market reference 1
50-day average
$1.2669
-21.30% below average
200-day average
$2.7001
-63.07% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-2.07M USD
P/E (TTM)
-0.03×
P/B (TTM)
0.08×
P/S (TTM)
3.15×
EV / EBITDA
0.49×
Earnings yield
-232.60%
Free cash flow yield
-190.24%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-311.76%
Operating margin
-34772.55%
Net margin
-33000.00%
Return on equity
-56.63%
Return on assets
-40.32%
Return on invested capital
-52.07%

Financial health

Debt / equity
0×
Current ratio
1.78×
Altman Z-score
-9.35
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3024%-8743%-20510%-32277%Gross margin, FY2022: 82.56%Gross margin, FY2025: -4864.71%Operating margin, FY2022: -10312.79%Operating margin, FY2025: -29335.29%Net margin, FY2022: -10223.26%Net margin, FY2025: -28458.82%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 82.56%. Gross margin FY2025 -4864.71%. Operating margin FY2022 -10312.79%. Operating margin FY2025 -29335.29%. Net margin FY2022 -10223.26%. Net margin FY2025 -28458.82%.

Income trends

Revenue

17K USD-80.23%

Operating income

−4.99M USD+66.01%

Net income

−4.84M USD+66.84%
Income trends across reported periods1.56M USD−4.34M USD−10.25M USD−16.15M USDRevenue, FY2022: 86K USDRevenue, FY2025: 17K USDOperating income, FY2021: −7.21M USDOperating income, FY2022: −8.87M USDOperating income, FY2023: −9.58M USDOperating income, FY2024: −14.67M USDOperating income, FY2025: −4.99M USDNet income, FY2021: −7.25M USDNet income, FY2022: −8.79M USDNet income, FY2023: −9.34M USDNet income, FY2024: −14.59M USDNet income, FY2025: −4.84M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 86K USD. Revenue FY2025 17K USD. Operating income FY2021 −7.21M USD. Operating income FY2022 −8.87M USD. Operating income FY2023 −9.58M USD. Operating income FY2024 −14.67M USD. Operating income FY2025 −4.99M USD. Net income FY2021 −7.25M USD. Net income FY2022 −8.79M USD. Net income FY2023 −9.34M USD. Net income FY2024 −14.59M USD. Net income FY2025 −4.84M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue17K USD——86K USD—
Cost of goods sold844K USD16K USD15K USD15K USD7K USD
Gross profit−827K USD−16K USD−15K USD71K USD−7K USD
Research and development1.14M USD11.71M USD6.04M USD4.42M USD2.86M USD
Selling, general, and administrative3.02M USD2.95M USD3.55M USD4.45M USD4.35M USD
Operating expenses4.16M USD14.66M USD9.58M USD8.87M USD7.21M USD
Interest income120K USD101K USD406K USD160K USD—
Interest expense10K USD14K USD384K USD61K USD10K USD
Depreciation and amortization774K USD16K USD15K USD15K USD7K USD
Operating income−4.99M USD−14.67M USD−9.58M USD−8.87M USD−7.21M USD
Net income−4.84M USD−14.59M USD−9.34M USD−8.79M USD−7.25M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
63%
5 beats, 3 misses, 0 met estimates
Average EPS surprise
-5184.24%
8 comparable reports
Latest EPS result
-7.47
Estimate -672 · Beat by 98.89%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-4.03-244.48-484.93-725.38Q3 '24BeatQ4 '24MissQ2 '25No estimateQ2 '25No estimateQ4 '25BeatQ1 '26BeatQ2 '26EstimateQ3 '26Estimate
Q3 2024, reported Aug 15, 2024: actual -47.99, estimate -124.8, surprise +61.55%, Beat. Q4 2024, reported Nov 21, 2024: actual -18.96, estimate -4.74, surprise -300.00%, Miss. Q2 2025, reported Apr 4, 2025: actual -15, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 7, 2025: actual -13.75, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Oct 1, 2025: actual -13.75, estimate -134.4, surprise +89.77%, Beat. Q1 2026, reported Mar 26, 2026: actual -7.47, estimate -672, surprise +98.89%, Beat. Q2 2026, reported Apr 6, 2026: actual —, estimate -672, surprise —, Comparison unavailable. Q3 2026, reported Jul 2, 2026: actual —, estimate -612, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates18.36K11.79K5.21K-1.36KQ2 '24No estimateQ1 '26MetQ2 '26EstimateQ3 '26Estimate
Q2 2024, reported May 15, 2024: actual 0 USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 26, 2026: actual 17K USD, estimate 17K USD, surprise 0.00%, Met estimate. Q2 2026, reported Apr 6, 2026: actual —, estimate 15.82K USD, surprise —, Comparison unavailable. Q3 2026, reported Jul 2, 2026: actual —, estimate 14.72K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution

PRFX news

globenewswire.com

PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch Interim CEO Efraim…

Read source
globenewswire.com

PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026

TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that its DeepSolar business unit will participate in Energy Trading Week Europe 2026,…

Read source
globenewswire.com

PRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage Assets

New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solution Advances Toward Planned Commercial Launch New Capability Builds on Recently Completed Real-World Validation of…

Read source
globenewswire.com

PRF Technologies' DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data

Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Utility-Scale Renewable…

Read source
globenewswire.com

PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark

Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting,…

Read source
feeds.benzinga.com

Why Is PRF Tech Stock Falling On Monday?

PRF Technologies (NASDAQ: PRFX) stock falls sharply Monday morning. Read why analysts see this as a market correction after Friday's 186% surge.

Read source

Corporate actions

Corporate action history

Stock split

Effective Feb 6, 2026

1:5

Stock split

Effective Nov 21, 2024

1:4

Stock split

Effective Sep 9, 2024

1:6

Stock split

Effective Jul 3, 2023

1:10

PRFX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research PRFX

research.disclaimer